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Sp ¼ <0.001). Reduction in LV volumes was seen in both functional and degenerative
MR subtypes. LA volumes decreased an average of 29 ml (p ¼0.009) after successful
SR, but LA volumes were only reduced signiﬁcantly in the PR group when residual
MR severity was  1+ (reduction of 14 ml, p¼0.0016). (Table 1).
Conclusions: Favorable LV remodeling occurred after successful PR, however
improvements were less robust compared to SR at 4 years. LA volumes improved
signiﬁcantly after successful SR, but only after PR when residual MR was 1+.
Further study should inform whether the degree of reverse remodeling impacts long-
term clinical outcomes and MitraClip durability.P
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All £2+ LVEDVI
(ml/m2)
15033
(61)
12134
(59)
-2929 <0.001 16247
(39)
11342
(35)
-5132 <0.001 <0.001
LVESVI
(ml/m2)
6122
(61)
5224
(59)
-819 0.0018 6128
(39)
4929
(35)
-1317 <0.001 0.2
LA
volume
(ml)
7824
(59)
7326
(59)
-523 0.11 8133
(37)
5220
(33)
-2822 <0.001 <0.001
LVEF% 609.0
(61)
589
(59)
-28 0.06 639
(39)
5811
(35)
-49 0.009 0.2
All £1+ LVEDVI
(ml/m2)
15135
(28)
11426
(28)
-3426 <0.001 15844
(35)
10633
(31)
-5332 <0.001 0.019
LVESVI
(ml/m2)
6425
(28)
4817
(28)
-1517 <0.001 5620
(35)
4422
(31)
-1316 <0.001 0.61
LA
volume
(ml)
7920
(28)
6720
(27)
-1420 0.0016 8134
(33)
4919
(31)
-2921 <0.001 0.009
LVEF % 5811
(28)
5810
(28)
110 0.72 656
(35)
6010
(29)
-510 0.0085 0.035
basal post ES post nitro
basal after
Clip
Post ES
after Clip
average Peak gradient
(mmHg)
5627 13423 8428 106 229
patient #1 PP-gradient 36.0 136.0 55.0 3.0 19.0
patient #2 PP-gradient 75.0 150.0 120.0 7.0 35.0
patient #3 PP-gradient 84.0 150.0 90.0 13.0 16.0
patient #4 PP-gradient 30.0 100.0 70.0 17.0 18.0
average Mean gradient
(mmHg)
4113 8933 6121 135 217
SAM ++ +++ +++ 0 +
MR (grade) 2.60.25 3.00 3.00 0.50.4 0.630.25
patient #1 mean
transmitral gradient
3.0 n.a. n.a. 5.0 n.a.
patient #2 mean
transmitral gradient
2.0 n.a. n.a. 3.0 n.a.
patient #3 mean
transmitral gradient
3.0 n.a. n.a. 3.0 n.a.
patient #4 mean
transmitral gradient
3.0 n.a. n.a. 6.0 n.a.TCT-86
The 2011-12 Pilot European Sentinel Registry of Percutaneous Edge-to-Edge
Mitral Valve Repair: In-hospital results and mid-term follow up of 587 patients
Rodrigo Estevez1, Georg Nickenig2, Stephan Baldus3, Magnus Settergren4,
Carlo Di Mario5, Neil Moat6, Anna Sonia Petronio7, Salvatore Scandura8,
Klaus Tiroch9, Olaf Franzen10
1HemoLeon, Fundación Investigación Sanitaria en León, Leon, Leon, 2University
Hospital Bonn, Bonn, Germany, 3University Heart Center Hamburg, Hamburg,
Hamburg, 4Karolinska Hospital, Stocholm, Sweden, 5Imperial College London,
London, United Kingdom, 6royal brompton hospital, London, United Kingdom,
7University of Pisa, Pisa, Italy, 8Ferraroto Hospital, Catania, Italy, 9HELIOS
Klinkum, Wuppertal, Germany, 10Rigshospitalet Copenhagen, Copenhagen, Denmark
Background: Edge-to-edge percutaneous mitral valve repair has emerged as an
alternative to surgery in high-risk patients. However, data with regard to its safety and
efﬁcacy in real-world patients are still scarce. The aim of this prospective multina-
tional registry is to present a real-world overview of MitraClip use focusing on patient
characteristics, clinical indication, technique, in-hospital and mid-term outcome.
Methods: The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective
independent consecutive collection of individual patient data entered into a web-based
case record form (CRF).
Results: A total of 587 patients (mean age 74.79.5 years, 64.1 % male) underwent
MitraClip implantation between January 2011 and December 2012 in 25 centres of 8
European countries. The prevalent etiology was functional MR (FMR; 414 patients,
70.5%) while 150 patients (25.5%) were diagnosed as having degenerative MR
(DMR), with the remaining patients (23, 4.0%) classiﬁed as mixed aetiology or MR of
unknown origin.Logistic EuroSCORE was high (19.916.0%). Successful deploy-
ment of at least 1 clip was achieved in 95.9% of patients, with a trend to higher
implantation success in the FMR group (p¼0.087). Acute procedural success was high
(97.3%) and equivalent between groups (p¼1.000). One clip was implanted in the
majority of cases (60.7%), two clips were implanted in 35.9% of cases and a small
minority received 3 or more clips (3.4%). Patients with DMR tended to receive
a greater number of clips (2 clips implanted in 43.5% of patients with DMR vs.
37.4% of patients with FMR, p¼0.191) than those with functional mitral regurgitation.
Echocardiograms prior to discharge showed a marked reduction in mitral insufﬁciency
to 2+ in 98.2% of patients, with equivalence between groups. In-hospital mortality
was low (2.0%) and without signiﬁcant differences between groups, although DMR
group had a trend to higher mortality. Clinical and echo follow-up data at 6-12 month
will be available at the time of presentation.B28 JACC Vol 62/18/Suppl B j October 27–November 1, 2013Conclusions: this truly independent and contemporary registry of MitraClip
implantation shows that the technique is effective and is associated with low
complication rate.
TCT-87
Targeting systolic anterior motion and left ventricular outﬂow tract obstruction
in hypertrophic obstructed cardiomyopathy with a MitraClip
Ulrich Schaefer1, Christian Frerker1, Felix Kreidel1, Karl-Heinz Kuck1
1Asclepios Clinics St. Georg, Hamburg, Germany
Background: Hypertrophic obstructive cardiomyopathy (HOCM) with left ventric-
ular outﬂow tract obstruction frequently involves a systolic anterior motion (SAM) of
the anterior mitral leaﬂet. We hypothesized, that SAM could be a new target for
MitraClip therapy.
Methods: Four patients with HOCM were chosen for MitraClip therapy, due to
signiﬁcant SAM with subsequent mitral regurgitation. Invasive hemodynamic studies
(right heart catheterization, simultaneous transaortic pressure recording, administra-
tion of nitroglycerin) before and after MitraClip implantation in addition to 6 weeks
follow-up were performed.
Results: MitraClip implantation was successfully performed with signiﬁcant reduc-
tion of mitral regurgitation and SAM in all patients. Basal peak gradients (before Clip:
5627 mmHg; after clip: 106 mmHg) as well as provoked pressure gradients
(before clip: 13423 mmHg; after clip: 218 mmHg) were signiﬁcantly reduced after
MitraClip. Right heart catheterization data did not reveal major changes. At 6-weeks
follow-up, all patients presented in a persistent improved clinical state (NYHA class I-
II) with insigniﬁcant residual MR and continuously reduced LVOT gradients.
Conclusions: This is the ﬁrst catheter-based study targeting primarily a SAM in
HOCM to reduce LVOT obstruction. The results prove the concept, that SAM is more
than an epiphenomenon in HOCM. Thus, SAM-induced obstruction might be
a valuable target for the MitraClip.TCT-88
Outcomes of Cardiac Surgery are Preserved Following the MitraClip Procedure.
Alfredo Trento1, Wen Loong Yeow1, Takashi Matsumoto1, Asma Hussaini1,
Swaminatha V. Gurudevan1, Takahiro Shiota1, Saibal Kar1
1Cedars-Sinai Medical Center, Los Angeles, CA
Background: Transcatheter mitral valve repair with the MitraClip is a safe procedure
for severe mitral regurgitation (MR). A reported higher mitral valve replacement rate
following the MitraClip resulted in an overstated complexity of subsequent surgery
and its implications on patient outcomes. This study will review the outcomes of
cardiac surgery following MitraClip procedure.
Methods: Of the 157 consecutive patients that underwent the MitraClip procedure in
our center, 16 (10%) required cardiac surgery. These patients (mean 6712 years old,
7 (44%) women) with Society of Thoracic Surgeons mortality score of 0.5 to 17.1%
were reviewed in regards to their operative details and outcomes. The mean implant
duration was 12.5 months (range 14 days to 75 months).
Results: No patient required urgent cardiac surgery for failed MitraClip procedure. Of
the 9 patients with degenerative MR, 8 were repaired and 1 had a replacement for
MitraClip endocarditis. Robotic assisted repair occurred in one patient that had no
implanted clip whilst 2 had one clip, and 3 had two clips; the implant duration ranged
from 2.5 months to 6.3 years. Of the 7 patients with functional MR, 5 had replacement
and 2 required heart transplantation for severe heart failure. There was no operativej TCT Abstracts/ORAL/Percutaneous Treatment of Mitral Valve Disease
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 1:00 PM–3:15 PM
O
R
A
Lmortality at 30 days, with one death in a patient with functional MR after 5.8 years and
a degenerative MR patient after 3.2 years. There were no strokes with an average
follow-up of 2.41.8 years. There were sustained improvements in New York Heart
Association class (from 2.8  0.6 to 1.6  0.5, p <0.001) and MR grade (from 3.5 
0.9 to 0.4  0.5, p <0.001) at follow-up.
Conclusions: In this large single center experience, no patient required urgent cardiac
surgery for failed MitraClip procedure. Mitral valve repair rate in patients with
degenerative MR was high, and surgical options were preserved in the remaining
patients. Overall, cardiac surgical outcomes were excellent.
TCT-89
Percutaneous Leaﬂet Therapy of Severe Primary Mitral Regurgitation: Totality
of Evidence From the EVEREST II Randomized, Continued Access, and High
Risk Clinical Programs
Saibal Kar1, Scott Lim2, Vivek Rajagopal3, Tanvir Bajwa4, Ramon Quesada5,
John Carroll6, Elyse Foster7, Neil Weissman8, Alfredo Trento9, Michael Mack10,
Donald Glower11, Ted Feldman12
1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of Virginia,
Charlottesville, United States, 3Piedmont Healthcare, Atlanta, GA, 4ACS, Aurora
Sinai/St. Luke's Med Ctrs, Univ Wisconsin School of Medicine and Public Health,
Milwaukee, WI, 5Baptist Hospital of Miami, Miami, FL, 6University of Colorado,
Aurora, CO, 7University of California, San Francisco, San Francisco, CA, 8MedStar
Washington Hosp Center, Washington, DC, 9Cedars-Sinai Medical Center, Los
Angeles, California, 10Baylor Healthcare System, Plano, United States, 11Duke
University Medical Center, Durham, North Carolina, 12Evanston Hospital, Evanston,
United States
Background: In primary or degenerative mitral regurgitation (DMR), the mitral valve
(MV) leaﬂets are structurally abnormal. The MitraClip device is the only percutaneous
leaﬂet-based therapy evaluated by both randomized and registry-based studies
utilizing core lab evaluation of patients with moderate to severe or severe ( 3+)
DMR. Functional MR has been separately and previously evaluated.
Methods: One-year data from the EVEREST II studies were analyzed for 509 patients
with severe baseline DMR, including 447 treated with MitraClip and 62 who
underwent a ﬁrst MV surgery.
Results: MV leaﬂet pathologies of prolapse and ﬂail were well-represented.
Compared to surgical candidates, high-risk DMR patients had STS mortality risk
scores of 12%, or surgeon assessment of excessive risk based on pre-speciﬁed
factors. They were older, more frequently had serious baseline co-morbidities, and
had more severe functional impairment than DMR patients in the RCT (Table 1).
Implant rates were consistently high across MitraClip DMR cohorts. Safety
outcomes reﬂected patient risk status. Lower-risk DMR patients who underwent
MV surgery had more complete MR reduction and greater improvement in LV
volumes than did lower-risk DMR patients who received MitraClip. Despite their
burden of co-morbidities, a large proportion of high-risk DMR patients who
received MitraClip achieved and maintained MR reduction to 2+ or less and did
not undergo MV surgery.Table 1. Baseline characteristics and outcomes* in EVEREST II High Risk (a)
and Low/Moderate Risk (b-d) DMR Cohorts
Baseline / Outcomes
(a). High Risk
MitraClip
(n=130)
(b). Continued
Access MitraClip
(n=187)
(c). RCT
MitraClip
(n=130)
(d). RCT
Surgery
(n=62)
Age 82  9 yrs 75  12 yrs 67  13 yrs 63  13 yrs
Coronary Artery Disease 74% 40% 37% 32%
Previous cardiovascular
surgery
52% 13% 12% 10%
Atrial Fibrillation 72% 53% 30% 29%
STS mortality risk score 13.6  8.4% n/a 3.7 3.1% 3.1  2.9%
LV Ejection Fraction 60  10% 60  7% 64  6% 65  6%
Anterior/Bileaﬂet Flail/
Prolapse
47% 39% 45% 35%
Posterior Flail/Prolapse 42% 50% 52% 61%
Mortality at 30 days 7.0% 1.1% 1.5% 3.2%
Major Adverse Events at 30
days
17.2% 10.2% 13.8% 51.6%
Freedom from MR >2+ at
1 year in surviving patients
86% 79% 84% 100%
Improvement in LVEDV at 1
year
-20  23 ml -13  22 ml -28  29 ml -48  36 ml
NYHA Class III/IV: Baseline
/ 1 year
79%/ 13% 52%/ 7% 41%/ 2% 39%/ 4%
Improvement in SF-36 PCS
at 1 year
5.9  8.9 6.2  8.9 5.2  9.8 4.2  10.6
*Echo data pending ﬁnal core lab review; MAE data pending ﬁnal CEC adjudication
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: In the EVEREST II DMR experience, the safety proﬁle of the MitraClip
has been demonstrated in both high risk and lower risk cohorts. While surgery was
more effective in lower risk DMR patients, MitraClip provides meaningful
improvements of LV volumes, NYHA Class and Quality of Life in all DMR patient
cohorts, demonstrating that the MitraClip is an important therapeutic option for select
DMR patients.
TCT-90
MitraClip Therapy in Patients at High Surgical Risk: Classiﬁcation Tree
Analysis to Reveal the Interrelation of Baseline Echocardiographic Variables
Impacting Acute Procedural Outcome
Michael Schlüter1, Eik Vettorazzi2, Volker Rudolph3, Edith Lubos1, Britta Goldmann1,
Daniel Lubs1, Hendrik Treede1, Johannes Schirmer1, Lenard Conradi1,
Hermann Reichenspurner1, Stephan Baldus3, Stefan Blankenberg1
1University Heart Center Hamburg, Hamburg, Germany, 2University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, 3University Hospital of Cologne, Cologne,
Germany
Background: Following CE approval in 2008, percutaneous mitral valve repair with
the MitraClip system (Abbott) has entered clinical practice in Europe, where it is
predominantly used to treat patients (pts) at high surgical risk. We sought to assess,
and elucidate the interrelation of, baseline echocardiographic variables predictive of
acute procedural failure in such pts.
Methods: The ﬁrst 300 consecutive pts (75  9 years, 190 men [63%]) who
underwent MitraClip therapy for grade 3+/4+ mitral regurgitation (MR) at our insti-
tution comprised the study cohort. All pts were adjudicated by heart team consensus as
not amenable to surgery. Procedural failure, deﬁned as discharge MR 3+, was
encountered in 32 patients (10.7%), with 11 aborted procedures (no clip implanted)
and 21 clip failures (MR 3+ despite clip implantation).
Results: Exact logistic regression analysis identiﬁed effective regurgitant oriﬁce area
(EROA), mitral valve oriﬁce area (MVOA), mean transmitral pressure gradient (TPG),
and MR severity (not quantiﬁed via EROA) as predictive of failure. Classiﬁcation tree
analysis (Figure) revealed EROA as the variable with highest discriminatory power,
followed by MVOA, TPG and MR severity. The highest incidence of clip failures
occurred in pts with EROA >0.71cm2, highest incidence of aborted procedures in pts
with MVOA 3.0cm2 and TPG 4mmHg.SConclusions: Baseline echocardiographic variables differentially impact the proce-
dural outcome of MitraClip therapy. Classiﬁcation tree analysis clariﬁes their inter-
relationship and may help to reduce the procedural failure rate.
TCT-91
MitraClip-Induced Acute Changes in Renal Function Impact Mortality in
Surgical High-Risk Patients with Signiﬁcant Mitral Regurgitation
Edith Lubos1, Daniel Lubs1, Michael Schlüter1, Mareike Donner1, Georg Sander1,
Johannes Schirmer1, Lenard Conradi1, Hendrik Treede1, Hermann Reichenspurner1,
Stephan Baldus2, Volker Rudolph2, Stefan Blankenberg1, Britta Goldmann1
1University Heart Center Hamburg, Hamburg, Germany, 2University Hospital of
Cologne, Cologne, Germany
Background: Impaired renal function (RF) is strongly associated with poor outcome
in patients (pts) with chronic heart failure (HF). We sought to assess the acute effect of
MitraClip therapy (MC) on RF and its impact on mortality and HF rehospitalization.
Methods: In a retrospective analysis of 306 surgical high-risk pts (74.4  8.7 years,
197 men [64.4%]) with grade 3+ mitral regurgitation (MR) treated by MC, we
calculated glomerular ﬁltration rate (GFR) at baseline (BL) and discharge from
creatinine levels (CKD-EPI formula). GFR was converted into the 5 Kidney Disease
Outcomes Quality Initiative (KDOQI) stages. Pts were followed for 16  11 (range,
0.3-41) months.
Results: MC acutely improved RF (DKDOQI <0) in 82 pts (27%) and worsened RF
(DKDOQI >0) in 31 pts (10%), with no change in 63% of pts. Overall, survival wasacts/ORAL/Percutaneous Treatment of Mitral Valve Disease B29
